PARIS--(BUSINESS WIRE)--Regulatory News: “We are delighted with this equity investment by Therabel. This confirms our European strategic partnership which will ensure the commercial success of Loramyc® and Setofilm®, both products registered by BioAlliance Pharma. Therabel thus emphasizes its strategy to invest in the supportive care area in the hospital setting” BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that Therabel has taken an equity stake in BioAlliance, according to the European licence agreement for Loramyc® and Setofilm® signed on March 31st 2010. Furthermore, the General Assembly Meeting, held on April 22, 2010, has adopted all the proposed resolutions, notably the change in the BioAlliance governance mode from a Supervisory Board to a Board of Directors.
